The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
Open accessAbstract
High viral and/or antigen load may be an important cause of the T cell hyporesponsiveness to hepatitis B virus (HBV) antigens that is often observed in patients with chronic HBV infection. Reduction of viral and antigen load by lamivudine treatment represents an ideal model for investigating this hypothesis. HLA class II restricted T cell responses and serum levels of HBV-DNA, HBsAg, and HBeAg were studied before and during lamivudine treatment in 12 patients with hepatitis B e antigen positive chronic active hepatitis B to assess possible correlations between viral and/or antigen load and vigor of the T cell response. Cell proliferation to HBV nucleocapsid antigens and peptides and frequency of circulating HBV nucleocapsid-specific T cells were assessed to characterize CD4-mediated responses. A highly significant enhancement of the CD4-mediated response to HBV nucleocapsid antigens was already detectable in most patients 7-14 d after the start of lamivudine treatment. This effect was dramatic and persistent in 10 patients but undetectable in 2. It occurred concomitant with a rapid and marked reduction of viremia. Interestingly, lamivudine also enhanced the responses to mitogens and recall antigens, showing that its effect was not limited to HBV-specific T cells. In conclusion, an efficient antiviral T cell response can be restored by lamivudine treatment in patients with chronic hepatitis B concurrently with reduction of viremia, indicating the importance of viral load in the pathogenesis of T cell hyporesponsiveness in these patients. Since lamivudine treatment can overcome T cell hyporeactivity, combining lamivudine with treatments directed to stimulate the T cell response may represent an effective strategy to induce eradication of chronic HBV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Hepatitis B Virus Immunopathogenesis
Chisari, F. V. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.29 · Cited by 1,609
Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240
Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI
Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., & Mosmann, T. R. (1990) · Science · doi:10.1126/science.2161559 · Cited by 1,143
Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity
Webb, S., Morris, C., & Sprent, J. (1990) · Cell · doi:10.1016/0092-8674(90)90420-j · Cited by 876
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 800
Expression of Interleukin-10 Activity by Epstein-Barr Virus Protein BCRF1
Hsu, D.-H., Malefyt, R. D. W., Fiorentino, D. F., Dang, M.-N., Vieira, P., deVries, J., Spits, H., Mosmann, T. R., & Moore, K. W. (1990) · Science · doi:10.1126/science.2173142 · Cited by 535
T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis
Critchfield, J. M., Racke, M. K., Zúñiga-Pflücker, J. C., Cannella, B., Raine, C. S., Goverman, J., & Lenardo, M. J. (1994) · Science · doi:10.1126/science.7509084 · Cited by 524
Doong, S. L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 516
Ferrari, C., Penna, A., Bertoletti, A., Valli, A., Antoni, A. D., Giuberti, T., Cavalli, A., Petit, M. A., & Fiaccadori, F. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.10.3442 · Cited by 505
Self-citation
Cited by
Immunology of hepatitis B virus and hepatitis C virus infection
Rehermann, B., & Nascimbeni, M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1573 · Cited by 1,627
Liaw, Y.-F., & Chu, C.-M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60207-5 · Cited by 1,218
Type 1/Type 2 Immunity in Infectious Diseases
Spellberg, B., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/317537 · Cited by 911
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
“Fortunately, treatment of CH-B patients with potent nucleos/tides such as lamivudine and adefovir dipivoxil can result in partial restoration of immune responses which are necessary for the durable host-mediated control of infection 39,40 (Cooksley et al., submitted).”
BackgroundManagement of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
T Cell Dynamics in HIV-1 Infection
Douek, D. C., Picker, L. J., & Koup, R. A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141053 · Cited by 571
McConkey, S. J., Reece, W. H. H., Moorthy, V. S., Webster, D., Dunachie, S., Butcher, G., Vuola, J. M., Blanchard, T. J., Gothard, P., Watkins, K., et al. (2003) · Nature Medicine · doi:10.1038/nm881 · Cited by 553
Bertoletti, A., & Ferrari, C. (2012) · Gut · doi:10.1136/gutjnl-2011-301073 · Cited by 477
Self-citationPerrillo, R. P. (2001) · Gastroenterology · doi:10.1053/gast.2001.22461 · Cited by 421
Boni, C., Laccabue, D., Lampertico, P., Giuberti, T., Viganò, M., Schivazappa, S., Alfieri, A., Pesci, M., Gaeta, G. B., Brancaccio, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.014 · Cited by 377
Self-citationMaini, M. K., Boni, C., Ogg, G. S., King, A. S., Reignat, S., Lee, C. K., Larrubia, J. R., Webster, G. J. M., McMichael, A. J., Ferrari, C., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70289-1 · Cited by 366
Self-citationBoni, C., Penna, A., Ogg, G. S., Bertoletti, A., Pilli, M., Cavallo, C., Cavalli, A., Urbani, S., Boehme, R., Panebianco, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.23045 · Cited by 339
Self-citationSong, B.-C., Suh, D. J., Lee, H. C., Chung, Y.-H., & Lee, Y. S. (2000) · Hepatology · doi:10.1053/jhep.2000.16665 · Cited by 336
Lai, C., Rosmawati, M., Lao, J., Van Vlierberghe, H., Anderson, F. H., Thomas, N., & Dehertogh, D. (2002) · Gastroenterology · doi:10.1053/gast.2002.37058 · Cited by 302
Kinetics of the Immune Response During Hbv and Hcv Infection
Bertoletti, A., & Ferrari, C. (2003) · Hepatology · doi:10.1053/jhep.2003.50310 · Cited by 254
Self-citationNan, X.-P., Zhang, Y., Yu, H.-T., Li, Y., Sun, R.-L., Wang, J.-P., & Bai, X.-F. (2010) · Viral Immunology · doi:10.1089/vim.2009.0061 · Cited by 37
“Boni et al. (4,6) found that lamivudine treatment, accompanied by a decline in patient viral load, can restore the host immune response, including T-helper cells and cytotoxic T-cell activity.”
Metadata
- Authors
- Boni, C., Bertoletti, A., Penna, A., Cavalli, A., Pilli, M., Urbani, S., Scognamiglio, P., Boehme, R., Panebianco, R., Fiaccadori, F., & Ferrari, C.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-09-01
- Volume
- 102
- Issue
- 5
- Pages
- 968-975
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2069030584
- Cited by
- 459
- References
- 21
- FWCI
- 21.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.